12:00 AM
Mar 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Calcitonin salmon regulatory update

FDA's Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee voted 12-9 that the overall benefit-risk assessment does not support the continued marketing of calcitonin salmon to treat osteoporosis in women >5 years after menopause. The committees also voted 20-1 that calcitonin products under development should be required...

Read the full 250 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >